As of 2026-03-20, the Relative Valuation of Aligos Therapeutics Inc (ALGS) is (81.82) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.34 USD, the upside of Aligos Therapeutics Inc based on Relative Valuation is -1214.8%.
The range of the Relative Valuation is (73.25) - (84.97) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.6x - 22.9x | 20.6x |
| Forward P/E multiples | 17.8x - 21.6x | 21.0x |
| Fair Price | (73.25) - (84.97) | (81.82) |
| Upside | -1097.9% - -1257.6% | -1214.8% |
| Date | P/E |
| 2026-03-18 | -1.77 |
| 2026-03-17 | -1.86 |
| 2026-03-16 | -1.96 |
| 2026-03-13 | -1.92 |
| 2026-03-12 | -1.88 |
| 2026-03-11 | -1.92 |
| 2026-03-10 | -1.80 |
| 2026-03-09 | -1.79 |
| 2026-03-06 | -1.77 |
| 2026-03-05 | -1.69 |
| 2026-03-04 | -1.74 |
| 2026-03-03 | -1.74 |
| 2026-03-02 | -1.77 |
| 2026-02-27 | -1.79 |
| 2026-02-26 | -1.91 |
| 2026-02-25 | -1.76 |
| 2026-02-24 | -1.80 |
| 2026-02-23 | -1.76 |
| 2026-02-20 | -1.73 |
| 2026-02-19 | -1.81 |
| 2026-02-18 | -1.73 |
| 2026-02-17 | -1.70 |
| 2026-02-13 | -1.76 |
| 2026-02-12 | -1.78 |
| 2026-02-11 | -1.90 |
| 2026-02-10 | -1.83 |
| 2026-02-09 | -1.84 |
| 2026-02-06 | -1.86 |
| 2026-02-05 | -1.65 |
| 2026-02-04 | -1.80 |
| 2026-02-03 | -1.91 |
| 2026-02-02 | -2.02 |
| 2026-01-30 | -2.05 |
| 2026-01-29 | -2.06 |
| 2026-01-28 | -2.05 |
| 2026-01-27 | -2.18 |
| 2026-01-26 | -2.13 |
| 2026-01-23 | -2.06 |
| 2026-01-22 | -2.17 |
| 2026-01-21 | -2.03 |
| 2026-01-20 | -2.04 |
| 2026-01-16 | -2.02 |
| 2026-01-15 | -2.10 |
| 2026-01-14 | -2.30 |
| 2026-01-13 | -2.35 |
| 2026-01-12 | -2.21 |
| 2026-01-09 | -2.29 |
| 2026-01-08 | -2.63 |
| 2026-01-07 | -2.45 |
| 2026-01-06 | -2.23 |